Related Experiment Video
Updated: Aug 14, 2026
13:42
Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
Published on: March 8, 2013
Defibrotide as a possible anti-ischemic drug
1Division of Vascular Medicine, University Hospital St. Orsola, Bologna, Italy.
Seminars in Thrombosis and Hemostasis
|January 1, 1996
Summary
Defibrotide, a polydeoxyribonucleotide, shows promise as an anti-ischemic agent. It protects organs from damage caused by ischemia and shock by modulating inflammatory pathways and improving blood flow.
Area of Science:
- Pharmacology
- Biochemistry
- Medical Science
Background:
- Defibrotide is a polydeoxyribonucleotide derived from porcine organs.
- Initial research focused on its antithrombotic effects via fibrinolysis activation.
- Recent studies suggest significant anti-ischemic properties.
Purpose of the Study:
- To investigate the anti-ischemic potential of defibrotide.
- To explore the mechanisms underlying defibrotide's protective effects in ischemia.
- To evaluate defibrotide for therapeutic applications in ischemic conditions.
Main Methods:
- Experimental pharmacology studies in various animal models.
- Investigation of defibrotide's effects on arachidonic acid metabolism.
- Assessment of defibrotide's impact on polymorphonuclear leukocytes and blood rheology.
Main Results:
- Defibrotide demonstrated protective effects against myocardial, liver, and kidney ischemia.
- It modulated prostacyclin, prostaglandin E2, and leukotriene B4 levels.
- Favorable effects on blood rheology and reduced leukocyte incorporation into thrombi were observed.
Conclusions:
- Defibrotide exhibits significant anti-ischemic properties.
- Its mechanisms involve modulation of inflammatory mediators and improved hemorheology.
- Defibrotide warrants further clinical investigation for treating organ ischemia.
More Related Videos
Related Concept Videos
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...